(MedPage Today) — The FDA announced accelerated approval of sevabertinib (Hyrnuo) for HER2-positive non-small cell lung cancer (NSCLC).
The approval stipulates use in patients who already have received systemic therapy for NSCLC. At the same…
Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/118608
Author :
Publish date : 2025-11-19 21:19:00
Copyright for syndicated content belongs to the linked Source.
